2023 Diabetes HIV Treatment and Prevention Agents 
ALiEM - Pharm Pearls
OCTOBER 30, 2024
Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. Of note, screening is often required for insurance approval for substance use treatment. Our experience: Traditionally, ED physicians do not like ordering urine drug screens (UDS).
Pharmacy Times
JUNE 23, 2025
It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans. The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ID Stewardship
JUNE 19, 2025
AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.
Pharmacy Times
JUNE 16, 2025
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.
Pharmacy Times
JUNE 10, 2025
3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism. December 21, 2004. Subscribe Now!
Pharmacy Times
JULY 3, 2025
She emphasizes that treatment options are mostly supportive, making prevention through good hygiene and vaccination essential. As a result, RSV is often overlooked as a contributing agent to respiratory and especially cardiorespiratory disease.
PharmaShots
APRIL 25, 2023
This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M
Expert insights. Personalized for you.
161 
Let's personalize your content